Biopsy of Possible Sarcomas

Effective Date: November 2024



Clinical Practice Guideline SAR-006 – Version 2 www.ahs.ca/guru

Introduction

Sarcomas are often large, deep-seated masses that may occur in locations that are poorly accessible to biopsy. This document outlines recommendations by the AHS Provincial Sarcoma Tumor Team comprised of individuals from the departments of surgery, radiation oncology, pathology, radiology and medical oncology. It is our goal to ensure that potential sarcomas are biopsied and submitted in the proper manner (without compromise in management) in order to provide adequate material for diagnosis and/or molecular testing. This will result in optimized treatment and decrease incidence of re-biopsy due to insufficient tissue.

Guideline Questions

1. What is the optimal procedure for biopsy of possible sarcomas?

Search Strategy

This guideline was created using an informal literature search.

Target Population

The following recommendations apply to adult patients who require biopsy for possible sarcomas. Patients under the age of 18 years with suspicion of sarcoma should only be biopsied after consultation with a pediatric oncologist at the Alberta Children's Hospital or the Stollery Children's Hospital.

Recommendations

We strongly encourage physicians seeing patients suspected of having sarcomas or having patients recently diagnosed with sarcomas to contact a member of the Provincial Sarcoma Tumour Team in order to enable proper evaluation and work-up of patients. This will ensure that they are given the best surgical options and treatment available.

Contact information:

- CCI New Patient Referral Office 780-432-8732
- ACCC Sarcoma Nurse Coordinator 587-231-4349

SPECIMENS:

Biopsy specimens may be of the following types:

 Core Needle Biopsies – usually under diagnostic imaging guidance and often performed by radiologists. Creates minimal tissue damage and allows for flexibility in future surgical planning. This method of biopsy can occasionally leave some sarcomas unclassified and may underestimate grade, but is nevertheless the *preferred biopsy method*.

- Excisional Biopsies recommended only for small superficial lesions (above fascia). Incisions *should not* be oriented in the transverse plane, as this results in more extensive surgery if margins are found to be inadequate.
- 3. **Incisional Biopsies** usually only performed after discussion with multidisciplinary sarcoma team and often only by surgical oncologist. Allows for triage of material for molecular testing and improves sampling.

If a gastrointestinal stromal tumour (GIST) is suspected clinically, please refer to Provincial GIST guidelines:

http://www.albertahealthservices.ca/assets/info/hp/cancer/if-hp-cancer-guide-sar002-gist.pdf

SUBMISSION OF SPECIMENS FOR PATHOLOGIC EXAMINATION:

Core Needle Biopsies: Ideally, four-five (4-5) cores of tumor should be submitted, with the cores submitted as follows:

- Option 1: 4 5 cores submitted in a formalin-filled container.
- Option 2: 1 of the 5 cores may be submitted fresh, on saline-soaked gauze, and immediately transported to the laboratory (for freezing/research purposes, if proper consent forms completed), remaining cores divided in 2 formalin-filled containers as above. The frozen tissue can potentially be used for diagnostic purposes if needed i.e. if the cores submitted in formalin are non-diagnostic.

*** For bone tumours with an extraosseous soft tissue component, it is recommended that biopsies of both the bone and soft tissue are submitted for pathology, to increase diagnostic yield and better enable molecular testing.

If uncertain as to which biopsy approach should be used, please contact surgical oncologist.

The size of needle used should be *the largest gauge possible* that can safely be used in a given patient/clinical situation. Ideally, at least a *16 gauge* for soft tissue biopsies and *11 gauge* for bone biopsies is preferred [See Figure 1].

The needle used should enter the same skin puncture site and is then passed in different directions though the mass, ensuring diverse sampling of different regions of tumor. For retroperitoneal masses, a retroperitoneal approach is preferred to avoid tumor seeding. The anatomic approach for the biopsy should be chosen in anticipation of future surgery.

Incisional/Excisional Biopsies: submission of part of the tissue fresh/in saline (optional). This allows tissue to either be frozen for research purposes, provided there are proper consent forms completed.

Frozen Section: If sarcoma is mentioned in the differential diagnosis, submission of the specimen as per #2 is recommended.

Fine Needle Aspiration Biopsy (FNAB): Although a potentially valuable biopsy method to document *recurrent* or *metastatic* soft tissue tumors, we recommend *core needle biopsy* (or incisional biopsy if a lesion is easily accessible) in the initial workup of an **unknown** soft tissue mass. If core biopsy is being performed, FNA is not required, and should not be performed.



Figure 1. Examples of Tissue Yield Based on Needle Size.

References

Walker, JA, et al. The percutaneous needle biopsy is safe and recommended in the diagnosis of musculoskeletal masses. Cancer, 2000; 89(12):2677-2686

Yang, Y and Damron, T.A. Comparison of tru-cut biopsy and fine needle aspiration for diagnostic accuracy in musculoskeletal lesions. Presented at the Connective Tissue Oncology Society 9th Annual Scientific Meeting, Barcelona, Spain, Nov 6-8, 2003.

Personal correspondence with Dr. Christopher Fletcher, MD, FRCPath Professor and Director of Surgical Pathology. Brigham & Women's Hospital Boston, MA

Additional References:

Y.J. Yang, T.A. Damron Comparison of needle core biopsy and fine-needle aspiration for diagnostic accuracy in musculoskeletal lesions Arch. Pathol. Lab. Med., 128 (7) (2004)

Singh HK, Kilpatrick SE, Silverman JF. Fine needle aspiration biopsy of soft tissue sarcomas: utility and diagnostic challenges. Adv Anat Pathol. 2004;11:24-37.

Tuttle R, Kane JM 3rd. Biopsy techniques for soft tissue and bowel sarcomas. J Surg Oncol. 2015;111:504-512.

Ray-Coquard I, Ranchere-Vince D, Thiesse P, et al. Evaluation of core needle biopsy as a substitute to open biopsy in the diagnosis of soft-tissue masses. Eur J Cancer. 2003;39:2021-2025.

Welker JA, Henshaw RM, Jelinek J, Shmookler BM, Malawer MM. The percutaneous needle biopsy is safe and recommended in the diagnosis of musculoskeletal masses. Cancer. 2000;89:2677-2686.

Development and Revision History

This guideline was developed by a multidisciplinary working group comprised of members from the Alberta Provincial Sarcoma Tumour Team, external participants identified by the Working Group Lead, and a methodologist from the Guideline Resource Unit. The draft guideline was externally reviewed and endorsed by members of the Alberta Provincial Sarcoma Tumour Team who were not involved in the guideline's development, including surgical oncologists, radiation oncologists, medical oncologists, radiologists, nurses, pathologists, and pharmacists. A detailed description of the methodology followed during the guideline development process can be found in the <u>Guideline Resource Unit</u> <u>Handbook.</u>

This guideline was originally developed in 2022 and updated in 2024.

Levels of Evidence

Ι	Evidence from at least one large randomized,
	controlled trial of good methodological quality (low
	potential for bias) or meta-analyses of well-conducted
	randomized trials without heterogeneity
II	Small randomized trials or large randomized trials with
	a suspicion of bias (lower methodological quality) or
	meta-analyses of such trials or of trials with
	demonstrated heterogeneity
III	Prospective cohort studies
IV	Retrospective cohort studies or case-control studies
۷	Studies without control group, case reports, expert
	opinion

Strength of Recommendations

Α	Strong evidence for efficacy with a substantial clinical
	benefit; strongly recommended
В	Strong or moderate evidence for efficacy but with a
	limited clinical benefit; generally recommended
С	Insufficient evidence for efficacy or benefit does not
	outweigh the risk or the disadvantages (adverse
	events, costs, etc.); optional
D	Moderate evidence against efficacy or for adverse
	outcome; generally not recommended
Ε	Strong evidence against efficacy or for adverse
	outcome; never recommended

Maintenance

A formal review of the guideline will be conducted in 2026. If critical new evidence is brought forward before that time, however, the guideline working group members will revise and update the document accordingly.

Abbreviations

AHS, Alberta Health Services; CCA, Cancer Care Alberta; FNAB, fine needle aspiration biopsy; GIST, gastrointestinal stroma tumour

Disclaimer

The recommendations contained in this guideline are a consensus of the Alberta Provincial Sarcoma Tumour Team and are a synthesis of currently accepted approaches to management, derived from a review of relevant scientific literature. Clinicians applying these guidelines should, in consultation with the patient, use independent medical judgment in the context of individual clinical circumstances to direct care.

Copyright © (2024) Alberta Health Services

This copyright work is licensed under the <u>Creative Commons</u> <u>Attribution-NonCommercial-NoDerivative 4.0 International</u>

license. You are free to copy and distribute the work including in other media and formats for non-commercial purposes, as long as you attribute the work to Alberta Health Services, do not adapt the work, and abide by the other license terms. To view a copy of this license,

see https://creativecommons.org/licenses/by-nc-nd/4.0/.

The license does not apply to AHS trademarks, logos or content for which Alberta Health Services is not the copyright owner.

Funding Source

Financial support for the development of Cancer Care Alberta's evidence-based clinical practice guidelines and supporting materials comes from the Cancer Care Alberta operating budget; no outside commercial funding was received to support the development of this document.

All cancer drugs described in the guidelines are funded in accordance with the Outpatient Cancer Drug Benefit Program, at no charge, to eligible residents of Alberta, unless otherwise explicitly stated. For a complete list of funded drugs, specific indications, and approved prescribers, please refer to the *Outpatient Cancer Drug Benefit Program Master List*.

Conflict of Interest Statements

Dr. Sarah McKillop has nothing to disclose.

Dr. Carolyn O'Hara has nothing to disclose.

Derek Tilley has nothing to disclose.

Citation

McKillop S, O'Hara C (lead), Tilley D. Cancer Care Alberta, Alberta Health Services (2024). Clinical Practice Guideline on [Biopsy of Possible Sarcomas, Version 2]. Accessed [Month, Year]. Available from: www.ahs.ca/guru